水飞蓟宾葡甲胺联合胆宁片治疗酒精性肝炎患者疗效及其对血脂和氧化应激指标的影响

doi:10.3969/j.issn.1672-5069.2020.05.015

摘要/Abstract

摘要： 目的探讨应用水飞蓟宾葡甲胺联合胆宁片治疗酒精性肝炎患者疗效及其对血脂和氧化应激指标的影响。方法 2017年3月～2019年6月我院肝病科诊治的酒精性肝炎患者146例,被随机分为对照组(n=73例)和观察组(n=73例),分别给予胆宁片或胆宁片联合水飞蓟宾葡甲胺治疗3个月。使用UV1800紫外可见分光光度计测定血清超氧化物歧化酶(SOD)和丙二醛(MDA)水平,使用Thermo Trace 1310气相色谱质谱联用仪测定血清游离脂肪酸(FFA)含量。结果治疗后,观察组血清总胆固醇(TC)水平为(4.9±0.7)mmol/L,显著低于对照组【(5.5±1.2)mmol/L,P<0.05】,而血高密度脂蛋白(HDL-C)水平为(1.3±0.9)mmol/L,显著高于对照组【(1.0±0.5)mmol/L,P<0.05】,两组血甘油三酯(TG)和低密度脂蛋白(LDL-C)水平变化差异无统计学意义【分别为(1.7±0.3)mmol/L对(1.7±0.7)mmol/L和(3.2±0.4)mmol/L对(3.4±0.7)mmol/L,P>0.05】;治疗后,观察组血清丙氨酸氨基转移酶(ALT)水平为(35.9±7.7)U/L,显著低于对照组【(63.5±9.2)U/L,P<0.05】,天冬氨酸氨基转移酶(AST)水平为(39.5±6.3)U/L,显著低于对照组【(65.5±7.8)U/L,P<0.05】,谷氨酰转肽酶(GGT)水平为(123.8±6.6)U/L,显著低于对照组【(145.7±7.2)U/L,P<0.05】,碱性磷酸酶(ALP)水平为(57.3±12.5)U/L,显著低于对照组【(78.4±13.1)U/L,P<0.05】;治疗后,观察组血清SOD水平为(132.9±19.3)nmol/L,显著高于对照组【(105.5±12.6)nmol/L,P<0.05】,MDA水平为(9.5±2.3)nmol/L,显著低于对照组【(14.4±3.6)nmol/L,P<0.05】,游离脂肪酸(FFA)水平为(24.3±3.1)nmol/L,显著低于对照组【(30.2±3.3)nmol/L,P<0.05】。结论应用水飞蓟宾葡甲胺联合胆宁片治疗酒精性肝炎患者可以显著改善血脂水平,抑制氧化应激指标,短期具有保护肝功能的作用,值得临床进一步研究。

关键词: 酒精性肝炎, 水飞蓟宾葡甲胺, 胆宁片, 血脂, 氧化应激, 治疗 , ,

Abstract: Objective The aim of this study was to investigate the short-term efficacy of silybin meglumine and Danning tablet, a herbal medicine, combination in treatment of patients with alcoholic hepatitis (AH). Methods 146 consecutive patients with AH were recruited in our hospital between March 2017 and June 2019, and were randomly divided into control group (n=73) and observation group (n=73). The patients in the control group were given Danning tablets, and those in the observation group were treated with silybin meglumine and Danning combination for 3 months. Serum superoxide dismutase (SOD), alondialdehyde (MDA) and free fatty acid (FFA) were detected. Results Serum total cholesterol (TC) level in the combination group was (4.9±0.7)mmol/L, significantly lower than 【(5.5±1.2)mmol/L, P<0.05】, and high density lipoprotein cholesterol (HDL-C) was (1.3±0.9)mmol/L, much higher than 【(1.0±0.5)mmol/L, P<0.05】 in the control, and serum triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) levels in the two groups were not significantly different 【(1.7±0.3)mmol/L vs. (1.7±0.7)mmol/L and (3.2±0.4)mmol/L vs. (3.4±0.7)mmol/L, respectively, P>0.05】; serum alanine aminotransferase level was (35.9±7.7)U/L, serum aspartate aminotransferase level was (39.5±6.3)U/L, serum glutamyl transpeptidase level was (123.8±6.6)U/L, and serum alkaline phosphatase level was (57.3±12.5)U/L, all significantly lower than those in the control [(63.5±9.2)U/L,(65.5±7.8)U/L,(145.7±7.2)U/L and (78.4±13.1)U/L, respectively, P<0.05】; serum SOD level was (132.9±19.3)nmol/L, much higher than 【(105.5±12.6)nmol/L, P<0.05】, serum MDA level was (9.5±2.3)nmol/L, significantly lower than 【(14.4±3.6)nmol/L, P<0.05】, and serum FFA level was (24.3±3.1)nmol/L, much lower than 【(30.2±3.3)nmol/L, P<0.05】 in the control. Conclusion The administration of silybin meglumine and a herbal medicine combination in treatment of patients with AH might in short-term ameliorate blood lipid metabolism, inhibit oxidative stress and improve liver functions, which needs further multi-central investigations.

Key words: Alcoholic hepatitis, Silybin meglumine, Herbal medicine, Blood lipids, Oxidative stress, Therapy

卢泳宇, 刘昌江, 黄帅. 水飞蓟宾葡甲胺联合胆宁片治疗酒精性肝炎患者疗效及其对血脂和氧化应激指标的影响[J]. 实用肝脏病杂志, 2020, 23(5): 662-665.

Lu Yongyu, Liu Changjiang, Huang Shuai.. Very short-term efficacy of silybin meglumine and Danning tablet combination in treatment of patients with alcoholic hepatitis[J]. Journal of Practical Hepatology, 2020, 23(5): 662-665.

参考文献

[1] Chang Y, Ryu S, Sung KC, et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung health study. Gut, 2019, 68(9): 1667-1675.
[2] You M, Jogasuria A, Lee K, et al. Signal transduction mechanisms of alcoholic fatty liver disease: Emer Ging role of lipin-1. Curr Mol Pharmacol, 2017, 10(3): 226-236.
[3] Hsu JY, Lin HH, Hsu CC, et al. Aqueous extract of pepino (solanum muriactum ait) leaves ameliorate lipid accumulation and oxidative stress in alcoholic fatty liver disease. Nutrients, 2018, 10(7): 931-932.
[4] Jeong JY, Sohn JH, Baek YH, et al. New botanical drug, hl tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: a placebo-controlled, randomized, phase ii trial. World J Gastroenterol, 2017, 23(32): 5977-5985.
[5] 李笠, 梁学亚. 水飞蓟宾葡甲胺联合多烯磷脂酰胆碱治疗酒精性肝炎患者初步临床研究. 实用肝脏病杂志, 2017, 20(4): 412-415.
[6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2): 170-176.
[7] Ahn JM, Paik YH, Min SY, et al. Relationship between controlled attenuation parameter and hepatic steatosis as assessed by ultrasound in alcoholic or nonalcoholic fatty liver disease. Gut Liver, 2016, 10(2): 295-302.
[8] Chen X, Ward SC, Cederbaum AI, et al. Alcoholic fatty liver is enhanced in cyp2a5 knockout mice: the role of the pparα-fgf21 axis. Toxicology, 2017, 379(10): 12-21.
[9] Wong T, Dang K, Ladhani S, et al. Prevalence of alcoholic fatty liver disease among adults in the United States. JAMA, 2019, 321(17): 1723-1725.
[10] Abenavoli L, Izzo AA, Mili N, et al. Milk thistle (silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res, 2018, 32(11): 2202-2213.
[11] 杜卫星, 叶青, 李金科, 等. 胆宁片联合瑞舒伐他汀治疗非酒精性脂肪性肝病患者HOMA-IR和血清TNF-α水平变化. 实用肝脏病杂志, 2017, 20(4): 490-491.
[12] Federico A, Dallio M, Loguercio C, et al. Silymarin/silybin and chronic liver disease: a marriage of many years. Molecules, 2017, 22(2): 11-12.
[13] Vecchione G, Grasselli E, Cioffi F, et al. The nutraceutic silybin counteracts excess lipid accumulation and ongoing oxidative stress in an in vitro model of non-alcoholic fatty liver disease progression. Front Nutr, 2017, 49(1): 41-42.
[14] 赵文霞, 张丽慧. 合理应用中成药治疗非酒精性脂肪性肝病. 实用肝脏病杂志, 2017, 20(2): 132-134.
[15] Zhang B, Xu D, She L, et al. Silybin inhibits nlrp3 inflammasome assembly through the nad₊/sirt2 pathway in mice with nonalcoholic fatty liver disease. FASEB J, 2018, 32(2): 757-767.
[16] Wang Y, Wu T, Hu D, et al. Intracellular hepatitis b virus increases hepatic cholesterol deposition in alcoholic fatty liver via hepatitis b core protein. J Lipid Res, 2018, 59(1): 58-68.
[17] Cui CX, Deng JN, Yan L, et al.Silibinin capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation. J Ethnopharmacol, 2017, 208(17): 24-35.
[18] 范建高, 徐正婕, 丁晓东, 等. 胆宁片对高脂饮食大鼠非酒精性脂肪性肝炎模型形成的影响. 实用肝脏病杂志, 2018, 10(3): 23-25.
[19] Abenavoli L, Greco M, Nazionale I, et al. Effects of mediterranean diet supplemented with silybin-vitamin e-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol, 2015, 9(4): 519-527.
[20] Tu LN, Showalter MR, Cajka T, et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Sci Rep, 2017, 7(1): 6118-6120.